Oncolytics Biotech Inc. · NASDAQ:ONCY
Oncolytics Biotech — Investor Presentation (October 2025)
21 slides from Oncolytics Biotech's investor presentation, October 2025
Slide 1: Pelareorep: a transformative dsRNA immunotherapy platform for gastrointestinal tumors
Oncolytics Biotech PELAREOREP a transformative dsRNA immunotherapy platform for gastrointestinal tumors October 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements Oncolytics Biotech Confidential This presentation is strictly confidential. Neither the Securities and Exchange Commission nor any state or foreign securities commission or regulatory authority has passed upon the adequacy or accuracy of this presentation. Any representati
Slide 3: Mission
MISSION We will leverage our proprietary product candidate, pelareorep (pela), an investigational first-in-class double-stranded RNA immunotherapeutic agent, to establish a platform immunotherapy for the treatment of gastrointestinal (GI) tumors. We believe GI tumors are the largest unmet medical ne
Slide 4: Pelareorep Proposed Mechanism of Action
PELAREOREP PROPOSED MECHANISM OF ACTION Oncolytics Biotech Pelareorep Treatment Cold Tumor Hot Tumor Tumor Under Attack Intravenous pela evades neutralization by Pela selectively infects and replicates in Pela infection kills some tumor cells by cell The pela-initiated inflammatory response results
Slide 5: Pelareorep Observed to Replicate in Almost All Evaluated Tumors
PELAREOREP HAS BEEN OBSERVED TO REPLICATE IN Oncolytics Biotech ALMOST ALL EVALUATED TUMORS Pela RNA is found in tumor but not stromal cells Pela is found in almost all on-treatment tumor biopsies Indication treated with IV Pela # of biopsied tumors # Pela-positive biopsies Pancreatic ductal 12 12 a
Slide 6: Broad Clinical Experience and Well-Understood Safety Results
BROAD CLINICAL EXPERIENCE AND WELL-UNDERSTOOD Oncolytics Biotech SAFETY RESULTS Pela has been >20 Oncolytics-sponsored studies Multiple cancer indications >1,200 patients treated, evaluated in and several externally sponsored (breast, pancreatic, colorectal, including >300 patients studies (NCI, CCT
Slide 7: Market Opportunity Within Pelareorep's Targeted Indications
MARKET OPPORTUNITY WITHIN PELAREOREP’S TARGETED INDICATIONS Oncolytics Biotech Gastrointestinal cancer is the fastest growing cancer in the world in people under 50 years old • ~ 500,000 patients globally1 1L Metastatic Pancreatic • ~ $3 billion total addressable market with 15% CAGR to 20322 Ductal
Slide 8: Pelareorep Clinical Development
PELAREOREP CLINICAL DEVELOPMENT
Slide 9: Clinical POC Across Targeted Indications Guides Strategic Sequencing
CLINICAL POC ACROSS TARGETED INDICATIONS GUIDES Oncolytics Biotech STRATEGIC SEQUENCING Targeted indication SOC benchmark* Pela Data Delta 2L mCRC (KRAS mutant) OS: 11.2 mo, PFS: 5.7 mo1 OS: 27 mo, PFS: 16.6 mo8 ~ 2-3x ≥2L SCAC ORR: 11-24%2-5 ORR: 30% ~ 1.5-3x 1L mPDAC 2-year OS rate: ~ 9%6, 7 2-yea
Slide 10: Clinical Development Pipeline
CLINICAL DEVELOPMENT PIPELINE Oncolytics Biotech Near-term rare disease opportunity in SCAC and long-term platform expansion in CRC and PDAC Program Collaborator Combination Phase 1 Phase 2 Registration-Enabling Phase 3 Anticipated Milestone 1L PDAC pela + GnP Expect to seek partnership Pivotal Stud
Slide 11: Pancreatic Cancer Program
PANCREATIC CANCER PROGRAM *Received FDA Fast Track & Orphan Drug Designations
Slide 12: Consistent Survival Benefit Observed in Multiple 1L mPDAC Studies
CONSISTENT SURVIVAL BENEFIT OBSERVED Oncolytics Biotech IN MULTIPLE 1L MPDAC STUDIES Clinical results of pelareorep in first-line mPDAC studies Company (Study) Description (Patients) 1-Year Survival 2-Year Survival Notes DCR: 83% vs. 33% Oncolytics Pelareorep + Gemcitabine (REO 017) 45% vs. 22% 24%
Slide 13: 2-Year Survival Rates in 1L Metastatic PDAC: Comparison to Landmark Studies
2-YEAR SURVIVAL RATES IN 1L METASTATIC PDAC: Oncolytics Biotech COMPARISON TO LANDMARK STUDIES 2-year Study 2-year Survival Rate survival 0% 10% 20% 30% Pela-based 21.9% REO 017: Pela + G therapy Pela-based 24.0% Comparator NCI 8601: Pela + CP therapy 20.0% Weighted mean = 21.9% treatment 9.2% arms
Slide 14: Colorectal Cancer Program
COLORECTAL CANCER PROGRAM ~ AeeR. ¥
Slide 15: Efficacy Results for Pelareorep in Colorectal Cancer Across Multiple Studies
EFFICACY RESULTS FOR PELAREOREP IN COLORECTAL CANCER Oncolytics Biotech DEMONSTRATED ACROSS MULTIPLE STUDIES REO 022 study in 2L KRAS mutant mCRC results more than double historical third-party benchmarks1, 2: • PFS: 16.6 months vs 5.7 months (pelareorep + FOLFIRI + bevacizumab vs. FOLFIRI + bevaciz
Slide 16: Anal Cancer Program
ANAL CANCER PROGRAM
Slide 17: Pela + Atezo in ≥2L SCAC
PELA + ATEZO IN ≥2L SCAC Oncolytics Biotech Strong efficacy signal with immunotherapy combination without chemo in difficult cancer 160% PD 140% 128% PD 120% 100% PD • 30% ORR in 20 evaluable patients Tumor Response % Change From Baseline 100% 79% PD 80% 60% PD PD PD • Awaiting feedback on 4 additio
Slide 18: Regulatory, Intellectual Property and Manufacturing
REGULATORY, INTELLECTUAL PROPERTY AND MANUFACTURING
Slide 19: Regulatory Strategy Based on Extensive Clinical Data
REGULATORY STRATEGY BASED ON EXTENSIVE CLINICAL DATA Oncolytics Biotech Trial Activities Indication Design Regulatory Strategy (estimated) • Proof of concept solidly established in three GI tumors 1L PDAC Randomized; 2H 2025 • Focus on most efficient regulatory path in high unmet Partnered medical n
Slide 20: IP Profile and Manufacturing Characteristics
IP PROFILE AND MANUFACTURING CHARACTERISTICS Oncolytics Biotech Intellectual Property Manufacturing • 147 patents issued worldwide • Non-genetically modified Reovirus • New patents expected to extend manufacturing • No special handling requirements and method of use protection into 2044 • High yield
Slide 21: Innovative Leadership Team with Strong Immuno-Oncology Expertise
INNOVATIVE LEADERSHIP TEAM WITH STRONG IMMUNO-ONCOLOGY, Oncolytics Biotech BUSINESS DEVELOPMENT, CLINICAL TRIAL AND FINANCE EXPERTISE Transactional expert Over 20 years of finance Nearly 30 years of drug having led more than 50 and accounting expertise development experience deals, including $2 bill
Oncolytics Biotech — Investor Presentation (October 2025) on 6ix